 World Generic Markets is the business publication designed to keep executives and industry analysts in touch with the latest developments in the world of generic pharmaceuticals.
Whether your interest is commercial, financial, regulatory or legal, no other business publication comes close to World Generic Markets (WGM) for providing such a comprehensive overview of developments in every area of the dynamic and rapidly growing generic drugs market. WGM takes the hard work out of staying in touch with:
 Manufacturers Products Alliances Patents/Litigation Pricing/Reimbursement Government policy.
WGM is available in print, email and web formats. The web version of WGM provides you with a regularly updated news service, while the pdf & paper issues provide a twice-monthly digest.
More info | Order now
Highlights from the current issue....
AMERICAS
USA: Barr shareholders approve Teva merger; Watson acquires products
USA: KV provides second quarter and six month estimates
USA: Cephalon and Eurand file patent lawsuit against Mylan and Barr
USA: Eli Lilly launches duloxetine lawsuit against Impax
USA: Perrigo settles desloratadine patent litigation
USA: Dr Reddy‟s launches sumatriptan authorised generic
USA: Teva gains budesonide approval; flurry of activity results
EUROPE
Germany: Stada reports nine month results
Hungary: Gedeon Richter announces nine month results
Slovenia: Krka reports nine month results
UK: SFO price fixing case appeal turned down
EU: EC publishes preliminary pharma competition report
UK: Government announces new drug price deal
ASIA/PACIFIC
India: PharmaZell opens production plant
MIDDLE EAST/AFRICA
Algeria: Actavis announces partnership
UAE: ProStrakan and NewBridge sign MEA agreement
|
 Biosimilars Business Review provides a review of, and commentary on, the developments that are shaping this rapidly evolving and often contentious sector of the generic drug industry.
Few areas of the generics market are proving as troublesome to develop as biosimilars. Unable to replicate reference products in the usual manner, companies are grappling with both production issues and regionally variable regulatory demands. Industry executives, regulators and commercial management operating in or monitoring this developing sector need to stay in close touch and, more importantly, be able to assess the significance of developments in a broader industry context.
This well written quarterly review will help you navigate through the twists and turns of the emerging biosimilar market. Packed with the latest industry and regulatory developments, company profiles and keen insightful commentary, it is essential reading for everyone involved or interested in biosimilars.
BBR is available in print and email formats.
More info | Order now
Highlights from the current issue...
EU issues GCSF final approvals
On 16th September 2008, Teva Pharmaceutical Industries announced that the European Commission's Directorate
General for Enterprise and Industry granted the company marketing authorisation for its human granulocyte colony stimulating factor (G-CSF) product.
Insmed presents G-CSF bioequivalence results
On July 10th 2008, Insmed announced the results of human bioequivalence tests for its G-CSF product (INS-19). According to the company, the results demonstrate bioequivalence between INS-19 and Neupogen, the reference product manufactured by Amgen.
Orrin Hatch urges passage of S. 1695, Henry Waxman urges caution
Senator Orrin Hatch spoke briefly at the Biosimilars 2008 Conference held at the George Washington University on September 22nd.
UK lists EPO biosimilars in the British National Formulary
The latest edition of the UK’s British National Formulary
(BNF 56, September 2008) has listings for biosimilar
EPO products, for the first time. Binocrit, from Sandoz, is available in a range of unit sizes from 1,000 to 10,000.
|
